Drug Approval | September 30, 2022
Lupin receives US FDA approval for Mirabegron Extended-Release tablets
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
The companies will leverage their respective proprietary technology platforms
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Olympus Corp was the market leader for endoscopy devices, accounting for around 23% of the global market in 2021.
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Subscribe To Our Newsletter & Stay Updated
